ClinicalTrials.Veeva
Menu

Find clinical trials for Eczema in Charlotte, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Dermatitis
Atopic Dermatitis
Skin Diseases
Dyssomnias
Food Hypersensitivity
Hypersensitivity
Parasomnias

Eczema trials near Charlotte, NC, USA:

Topical Ruxolitinib Evaluation in Chronic Hand Eczema

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema...

Active, not recruiting
Hand Eczema
Drug: Ruxolitinib cream
Drug: Vehicle

Phase 2

Incyte
Incyte

Charlotte, North Carolina, United States and 35 other locations

This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).

Enrolling
Atopic Dermatitis Eczema
Drug: Placebo
Drug: ANB032

Phase 2

AnaptysBio
AnaptysBio

Charlotte, North Carolina, United States and 83 other locations

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Phase 3

Pfizer
Pfizer

Shelby, North Carolina, United States of America and 557 other locations

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Phase 3

Lilly
Lilly

Charlotte, North Carolina, United States of America and 320 other locations

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

Phase 3

Amgen
Amgen

Charlotte, North Carolina, United States and 429 other locations

The primary objectives of this study are to:* estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-tetanus...

Active, not recruiting
Atopic Dermatitis
Moderate-to-severe Atopic Dermatitis
Drug: Placebo
Drug: Rocatinlimab

Phase 3

Amgen
Amgen

Matthews, North Carolina, United States and 85 other locations

Status recently updated

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.

Enrolling
Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

Phase 3

Amgen
Amgen

Charlotte, North Carolina, United States and 201 other locations

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Active, not recruiting
Moderate-to-Severe Atopic Dermatitis
Drug: Nemolizumab

Phase 3

Galderma
Galderma

Shelby, North Carolina, United States and 342 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems